CAB39 Antikörper

Produktnummer ABIN7239215

Produktdetails anti-CAB39 Antikörper

Target: CAB39 (Calcium Binding Protein 39 (CAB39))

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CAB39 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Produktmerkmale: Polyclonal Antibody

Aufreinigung: Affinity purification

Immunogen: Synthetic peptide of human CAB39

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:500-1:2000, IHC 1:50-1:200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1.7 mg/mL

Buffer: PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Avoid freeze / thaw cycles.

Details zu CAB39

Target: CAB39 (Calcium Binding Protein 39 (CAB39))

Andere Bezeichnung: CAB39 (CAB39 Produkte)

Synonyme: CG4083 antikoerper, Dmel\\CG4083 antikoerper, Dmo25 antikoerper, dMo25 antikoerper, l(3)00274 antikoerper, mo25 antikoerper, fc06a03 antikoerper, zgc:86716 antikoerper, wu:fc06a03 antikoerper, MGC78903 antikoerper, CAB39 antikoerper, MO25 antikoerper, AA408805 antikoerper, AA960512 antikoerper, C78372 antikoerper, MO25alpha antikoerper, CG4083 gene product from transcript CG4083-RA antikoerper, calcium binding protein 39 antikoerper, calcium binding protein 39 L homeolog antikoerper, Cab39 protein antikoerper, Mo25 antikoerper, cab39 antikoerper, cab39.L antikoerper, CAB39 antikoerper, Bm1_33380 antikoerper, Cab39 antikoerper

Hintergrund: Peutz-Jeghers Syndrome (PJS) is a rare hereditary disease characterized by melanocytic macules of the lips, gastrointestinal hamartomatous polyps and an increased risk for many classes of cancer. The serine/threonine kinase LKB1 (also designated STK11) has been identified as the gene mutated in PJS. LKB1 activity increases upon the binding of a regulatory complex consisting of the STE20-related adaptor-alpha (STRAD alpha) pseudo kinase and the calcium binding protein 39 (MO25 alpha). STRAD and MO25 determine the subcellular localization of LKB1 by initiating its translocation from the nucleus to the cytoplasm, thus regulating the tumor suppressor activity of LKB1. The LKB1/STRAD/MO25 complex acts as an AMP-activated protein kinase kinase (AMPKK).

Molekulargewicht: 40 kDa

NCBI Accession: NP_057373

UniProt: Q9Y376

Pathways: AMPK Signaling